These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 35103814)

  • 1. [Are psychedelics fast acting antidepressant agents?].
    Gründer G; Brand M; Kärtner L; Scharf D; Schmitz C; Spangemacher M; Mertens LJ
    Nervenarzt; 2022 Mar; 93(3):254-262. PubMed ID: 35103814
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Contribution of serotonin 5-HT
    Ibi D
    Nihon Yakurigaku Zasshi; 2023 May; 158(3):229-232. PubMed ID: 36990794
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Psychedelics for treatment resistant depression: are they game changers?
    Kalfas M; Taylor RH; Tsapekos D; Young AH
    Expert Opin Pharmacother; 2023; 24(18):2117-2132. PubMed ID: 37947195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Efficacy of psychedelics in psychiatry, a systematic review of the literature].
    Berkovitch L; Roméo B; Karila L; Gaillard R; Benyamina A
    Encephale; 2021 Aug; 47(4):376-387. PubMed ID: 33888297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esketamine and Psilocybin-The Comparison of Two Mind-Altering Agents in Depression Treatment: Systematic Review.
    Psiuk D; Nowak EM; Dycha N; Łopuszańska U; Kurzepa J; Samardakiewicz M
    Int J Mol Sci; 2022 Sep; 23(19):. PubMed ID: 36232748
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classical Psychedelics as Therapeutics in Psychiatry - Current Clinical Evidence and Potential Therapeutic Mechanisms in Substance Use and Mood Disorders.
    Mertens LJ; Preller KH
    Pharmacopsychiatry; 2021 Jul; 54(4):176-190. PubMed ID: 33472250
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Psychedelics in the treatment of unipolar mood disorders: a systematic review.
    Rucker JJ; Jelen LA; Flynn S; Frowde KD; Young AH
    J Psychopharmacol; 2016 Dec; 30(12):1220-1229. PubMed ID: 27856684
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Psilocybin-assisted psychotherapy for depression: Emerging research on a psychedelic compound with a rich history.
    Pearson C; Siegel J; Gold JA
    J Neurol Sci; 2022 Mar; 434():120096. PubMed ID: 34942586
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force Report: Serotonergic Psychedelic Treatments for Major Depressive Disorder.
    Rosenblat JD; Husain MI; Lee Y; McIntyre RS; Mansur RB; Castle D; Offman H; Parikh SV; Frey BN; Schaffer A; Greenway KT; Garel N; Beaulieu S; Kennedy SH; Lam RW; Milev R; Ravindran AV; Tourjman V; Ameringen MV; Yatham LN; Taylor V
    Can J Psychiatry; 2023 Jan; 68(1):5-21. PubMed ID: 35975555
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial.
    Sloshower J; Skosnik PD; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC
    J Psychopharmacol; 2023 Jul; 37(7):698-706. PubMed ID: 36938991
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets.
    Sousa TR; Rema J; Machado S; Novais F
    Curr Top Med Chem; 2022; 22(15):1250-1260. PubMed ID: 34852736
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Next generation antidepressants with novel mechanisms for treatment resistant depression.
    Chen MH; Tu PC; Su TP
    Prog Brain Res; 2023; 278():149-168. PubMed ID: 37414491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
    Carhart-Harris RL; Bolstridge M; Day CMJ; Rucker J; Watts R; Erritzoe DE; Kaelen M; Giribaldi B; Bloomfield M; Pilling S; Rickard JA; Forbes B; Feilding A; Taylor D; Curran HV; Nutt DJ
    Psychopharmacology (Berl); 2018 Feb; 235(2):399-408. PubMed ID: 29119217
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Psilocybin-assisted therapy for depression: A systematic review and meta-analysis.
    Haikazian S; Chen-Li DCJ; Johnson DE; Fancy F; Levinta A; Husain MI; Mansur RB; McIntyre RS; Rosenblat JD
    Psychiatry Res; 2023 Nov; 329():115531. PubMed ID: 37844352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Psychedelics for Patients With Cancer: A Comprehensive Literature Review.
    White CM; Weisman N; Dalo J
    Ann Pharmacother; 2023 Sep; 57(9):1062-1075. PubMed ID: 36635883
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of Psychedelics in Treatment-Resistant Depression.
    Kamal S; Jha MK; Radhakrishnan R
    Psychiatr Clin North Am; 2023 Jun; 46(2):291-305. PubMed ID: 37149346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sub-acute effects of psilocybin on EEG correlates of neural plasticity in major depression: Relationship to symptoms.
    Skosnik PD; Sloshower J; Safi-Aghdam H; Pathania S; Syed S; Pittman B; D'Souza DC
    J Psychopharmacol; 2023 Jul; 37(7):687-697. PubMed ID: 37392016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increased amygdala responses to emotional faces after psilocybin for treatment-resistant depression.
    Roseman L; Demetriou L; Wall MB; Nutt DJ; Carhart-Harris RL
    Neuropharmacology; 2018 Nov; 142():263-269. PubMed ID: 29288686
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preclinical perspectives on the mechanisms underlying the therapeutic actions of psilocybin in psychiatric disorders.
    Wulff AB; Nichols CD; Thompson SM
    Neuropharmacology; 2023 Jun; 231():109504. PubMed ID: 36921889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Psilocybin compared with escitalopram for depression].
    Strous JFM
    Ned Tijdschr Geneeskd; 2022 Jan; 166():. PubMed ID: 35138714
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.